MedTrace Logo

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

NCT05201781 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 295

Last updated 2026-05-08

No results posted yet for this study

Summary

The purpose of this study is to collect long-term follow-up data on delayed adverse events after administration of ciltacabtagene autoleucel (cilta-cel), and to characterize and understand the long-term safety profile of cilta-cel.

Conditions

Interventions

DRUG

Cilta-cel

Participants who had received cilta-cel in previous studies will be followed up in this study. No additional study treatment will be administered to participants in this study.

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    lead INDUSTRY

Principal Investigators

  • Janssen Research & Development, LLC Clinical Trial · Janssen Research & Development, LLC

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-09
Primary Completion
2037-07-29
Completion
2042-06-01
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • China
  • France
  • Israel
  • Japan
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05201781 on ClinicalTrials.gov